1-5 of 5
Mark Winderlich
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Isabelle Fleury, Anthea Peters, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Dan Huang, Eva E. Waltl, Mark Winderlich, Sumeet Ambarkhane, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 183.
https://doi.org/10.1182/blood-2021-148302
Published: 2021
Journal Articles

Estimation of Long-Term Survival with Tafasitamab + Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Gilles Salles, MDPhD, Budhaditya Goswami, MD, Vincenzo Bagnardi, Debarshi Dey, Mark Winderlich, PhD, Sumeet Ambarkhane, MD MBBS, Dan Huang, Grzegorz S. Nowakowski, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-140398
Published: 2020
Journal Articles

MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study

Marc S Raab, MD PhD, Manik Chatterjee, MD, Hartmut Goldschmidt, MD, Hermine Agis, MD, Igor Blau, MD PhD, Hermann Einsele, MD, Monika Engelhardt, MD, Barbara Ferstl, MD, Martin Gramatzki, MD, Christoph Rollig, MD MSC, Katja Weisel, MD, Tiantom Jarutat, MD, Dominika Weinelt, MD, Mark Winderlich, PhD, Christian Peschel, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 153.
https://doi.org/10.1182/blood-2018-153
Published: 2018
Journal Articles

Single-Agent MOR208 in Relapsed or Refractory (R-R) Non-Hodgkin's Lymphoma (NHL): Results from Diffuse Large B-Cell Lymphoma (DLBCL) and Indolent NHL Subgroups of a Phase IIa Study

Wojciech Jurczak, MD PhD, Pier Luigi Zinzani, MD PhD, Gianluca Gaidano, MD PhD, Andre Goy, MD, Mariano Provencio, MD PhD, Zsolt Nagy, MD PhD, Tadeusz Robak, MD PhD, Kami J. Maddocks, MD, Christian Buske, Sumeet Ambarkhane, MD, Mark Winderlich, PhD, Maren Dirnberger-Hertweck, PhD, Jan Endell, PhD, Kristie A Blum, MD
Journal: Blood
Blood (2016) 128 (22): 623.
https://doi.org/10.1182/blood.V128.22.623.623
Published: 2016
Journal Articles

A Phase IIa, Open-Label, Multicenter Study of Single-Agent MOR00208, an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Kristie A. Blum, MD, Kami Maddocks, MD, Zsolt Nagy, MD, Pier Luigi Zinzani, MD PhD, Andre Goy, MD, Mariano Provencio, Tadeusz Robak, MD, Christian Buske, MD, Roman Pawel Korolkiewicz, MD, Mark Winderlich, Wojciech Jurczak, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3089.
https://doi.org/10.1182/blood.V124.21.3089.3089
Published: 2014